Idris, I. ., Zhang, R. ., Mamza, J. B., Ford, M. ., Morris, T. ., Banerjee, A. ., & Khunti, K. . (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207–2214. http://doi.org/10.1111/dom.14437
dapagliflozin
Birkeland, K. I., Bodegard, J. ., Banerjee, A. ., Kim, D. J., Norhammar, A. ., Eriksson, J. W., … Kadowaki, T. . (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75–85. http://doi.org/10.1111/dom.14189